Semaglutide delays 4‐hour gastric emptying in women with polycystic ovary syndrome and obesity

To evaluate the effect of once‐weekly subcutaneous semaglutide 1.0 mg on the late digestive period of gastric emptying (GE) after ingestion of a standardized solid test meal by using technetium scintigraphy, the reference method for this purpose.

[1]  K. Elkind-Hirsch,et al.  Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study. , 2022, Fertility and sterility.

[2]  C. Rayner,et al.  Acute Administration of the GLP-1 Receptor Agonist Lixisenatide Diminishes Postprandial Insulin Secretion in Healthy Subjects But Not in Type 2 Diabetes, Associated with Slowing of Gastric Emptying , 2022, Diabetes Therapy.

[3]  A. Drewes,et al.  Quantification of gastric emptying with magnetic resonance imaging in healthy volunteers: A systematic review , 2022, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[4]  W. Garvey.  New Horizons. A New Paradigm for Treating to Target with Second-Generation Obesity Medications , 2021, The Journal of Clinical Endocrinology and Metabolism.

[5]  C. Rayner,et al.  Plasma GLP-1 response to oral and intraduodenal nutrients in health and type 2 diabetes - impact on gastric emptying. , 2021, The Journal of clinical endocrinology and metabolism.

[6]  S. Atkin,et al.  The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence , 2021, Therapeutic advances in endocrinology and metabolism.

[7]  D. Skovgaard,et al.  The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity , 2020, Diabetes, obesity & metabolism.

[8]  M. Nauck,et al.  GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art , 2020, Molecular metabolism.

[9]  M. Horowitz,et al.  Glucagon‐like peptide‐1 receptor agonists and the appropriate measurement of gastric emptying , 2020, Diabetes, obesity & metabolism.

[10]  C. Malbert,et al.  Acute Effects of Lixisenatide on Energy Intake in Healthy Subjects and Patients with Type 2 Diabetes: Relationship to Gastric Emptying and Intragastric Distribution , 2020, Nutrients.

[11]  M. Camilleri,et al.  Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity. , 2020, Advances in experimental medicine and biology.

[12]  M. Clark,et al.  GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones and Regional Body Fat Stores in Adults with Obesity. , 2020, The Journal of clinical endocrinology and metabolism.

[13]  C. Kapitza,et al.  Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal‐related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes , 2019, Diabetes, obesity & metabolism.

[14]  Yuichiro Yamada,et al.  Magnitude of slowing gastric emptying by glucagon‐like peptide‐1 receptor agonists determines the amelioration of postprandial glucose excursion in Japanese patients with type 2 diabetes , 2019, Journal of diabetes investigation.

[15]  Hiroshi Mashimo,et al.  Advances in the physiology of gastric emptying , 2019, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[16]  M. Horowitz,et al.  Comparative effects of proximal and distal small intestinal administration of metformin on plasma glucose and glucagon‐like peptide‐1, and gastric emptying after oral glucose, in type 2 diabetes , 2018, Diabetes, obesity & metabolism.

[17]  J. Blundell,et al.  Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity , 2017, Diabetes, obesity & metabolism.

[18]  A. Zinsmeister,et al.  Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. , 2017, The lancet. Gastroenterology & hepatology.

[19]  J. Holst,et al.  Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo‐controlled, double‐blind, parallel‐group study , 2017, Diabetes, obesity & metabolism.

[20]  G. Finlayson,et al.  Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity , 2017, Diabetes, obesity & metabolism.

[21]  C. S. Shaw,et al.  Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. , 2016, Human reproduction.

[22]  Karen L Jones,et al.  The Glucagon-Like Peptide 1 Receptor Agonist Exenatide Inhibits Small Intestinal Motility, Flow, Transit, and Absorption of Glucose in Healthy Subjects and Patients With Type 2 Diabetes: A Randomized Controlled Trial , 2015, Diabetes.

[23]  J. Rosenstock,et al.  Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial , 2015, Diabetes Care.

[24]  R. Oikawa,et al.  Differing effects of liraglutide on gastric emptying in Japanese patients with type 2 diabetes , 2014, Diabetes, obesity & metabolism.

[25]  H. Durak,et al.  In Vitro Evaluation of Tc-99m Radiopharmaceuticals for Gastric Emptying Studies , 2014, Molecular imaging and radionuclide therapy.

[26]  B. Sloth,et al.  Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults , 2013, International Journal of Obesity.

[27]  A. Pietraszek,et al.  Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat‐rich meal in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled, cross‐over trial , 2013, Diabetes, obesity & metabolism.

[28]  M. Horowitz,et al.  Relationships Between Gastric Emptying, Postprandial Glycemia, and Incretin Hormones , 2013, Diabetes Care.

[29]  M. Camilleri,et al.  Performance characteristics of scintigraphic measurement of gastric emptying of solids in healthy participants , 2012, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[30]  C. Kapitza,et al.  Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. , 2012, Diabetes research and clinical practice.

[31]  A. Maurer,et al.  Procedure Guideline for Adult Solid-Meal Gastric-Emptying Study 3.0* , 2009, Journal of Nuclear Medicine Technology.

[32]  A. Zinsmeister,et al.  Optimizing analysis of stable isotope breath tests to estimate gastric emptying of solids , 2009, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[33]  D. Drucker,et al.  Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study , 2008, The Lancet.

[34]  D. Drucker,et al.  Biology of incretins: GLP-1 and GIP. , 2007, Gastroenterology.

[35]  A. Zinsmeister,et al.  Effect of female sex hormone supplementation and withdrawal on gastrointestinal and colonic transit in postmenopausal women , 2006, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[36]  Michael Horowitz,et al.  Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. , 2006, The Journal of clinical endocrinology and metabolism.

[37]  J. Holst,et al.  Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans , 2006, Diabetologia.

[38]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[39]  M. Camilleri,et al.  Gastric motor and sensory functions in obesity. , 2005, Obesity research.

[40]  J. Holst,et al.  Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man , 1993, Digestive Diseases and Sciences.

[41]  R. Fisher,et al.  American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. , 2004, Gastroenterology.

[42]  M. Camilleri,et al.  Independent influences of body mass and gastric volumes on satiation in humans. , 2004, Gastroenterology.

[43]  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. , 2004, Fertility and sterility.

[44]  M. Camilleri,et al.  Is there a role for gastric accommodation and satiety in asymptomatic obese people? , 2001, Obesity research.

[45]  A. Astrup,et al.  The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity , 2001, International Journal of Obesity.

[46]  A. Astrup,et al.  Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. , 1998, The Journal of clinical investigation.